APO-PROCAINAMIDE CAP 250MG 250 MG
PROCAINAMIDE HYDROCHLORIDE : 250 MG · DIN 00713325 · APOTEX INC
Health Canada status: CANCELLED POST MARKET
What is APO-PROCAINAMIDE CAP 250MG?
APO-PROCAINAMIDE CAP 250MG 250 MG contains PROCAINAMIDE HYDROCHLORIDE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00713325, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00713325 |
|---|---|
| Brand name | APO-PROCAINAMIDE CAP 250MG |
| Generic / active ingredient | PROCAINAMIDE HYDROCHLORIDE : 250 MG |
| Manufacturer | APOTEX INC |
| Strength | 250 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C01BA02 PROCAINAMIDE |
| AHFS class | 24:04.04.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Apr-2025 |
| Original market date | 1986-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C01BA02 PROCAINAMIDE. 1 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PROCAINAMIDE HYDROCHLORIDE INJECTION USP | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02184486 |
| APO-PROCAINAMIDE CAP 375MG | 375 G | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 00713333 |
| APO-PROCAINAMIDE CAP 500MG | 500 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 00713341 |
| PROCAINAMIDE-250 CAP 250MG | 250 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00731382 |
| PROCAINAMIDE-375 CAP 375MG | 375 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00731390 |
| PROCAINAMIDE-500 CAP 500MG | 500 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00728268 |
| PROCAN SR | 250 MG | TABLET (EXTENDED-RELEASE) | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | DIN 00638692 |
| PROCAN SR | 500 MG | TABLET (EXTENDED-RELEASE) | ERFA CANADA 2012 INC | CANCELLED POST MARKET | DIN 00638676 |
| PROCAN SR | 750 MG | TABLET (EXTENDED-RELEASE) | ERFA CANADA 2012 INC | CANCELLED POST MARKET | DIN 00638684 |
| PRONESTYL CAP 250MG | 250 MG | CAPSULE | SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 00029076 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.